Faruqi & Faruqi, LLP is Investigating PharMerica Corporation on Behalf of its Shareholders - PMC
Faruqi & Faruqi, LLP, a national law firm concentrating on investor rights, consumer rights and the enforcement of federal antitrust laws, is investigating potential claims against the Board of Directors of PharMerica Corporation (“PharMerica” or the “Company”) (NYSE: PMC) concerning possible breaches of fiduciary duty and other violations of law. The investigation concerns actions by PharMerica’s Board of Directors that have allegedly caused the Company to violate the False Claims Act (“FCA”) and the Controlled Substances Act (“CSA”).
Specifically, on August 9, 2013 the Department of Justice announced that it had filed a suit against PharMerica for violating the FCA and the CSA by dispensing controlled substances without valid prescriptions and causing claims for illegally dispensed drugs to be submitted for reimbursement under the Medicare program. The government’s complaint alleges that PharMerica routinely dispensed Schedule II controlled substances in non-emergency situations without first obtaining a written prescription from a treating physician. The complaint alleges that PharMerica knowingly caused the submission of false claims to Medicare for these improperly dispensed Schedule II drugs, in violation of the FCA.
Shareholders interested in seeking to recover damages on behalf of PharMerica and to implement corporate governance measures designed to prevent future misconduct should contact the firm.
If you hold PMC shares and you would like to discuss your legal rights, you can contact us by calling Michael J. Hynes free at 877-247-4292 or at 215-277-5770 or by sending an e-mail to firstname.lastname@example.org.
Please tell us about yourself by completing the form below and we will provide you with additional
information on how to join the Action.
* The submission of this form does not create an attorney-client relationship.
Faruqi & Faruqi, LLP
685 Third Avenue 26th Floor
New York, NY 10017
Tel: (212) 983-9330
If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.